Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis
NCT ID: NCT05765461
Last Updated: 2024-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4631 participants
OBSERVATIONAL
2019-12-31
2022-11-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Evaluation and Cutaneous Acceptability of the Lipikar Med Product on Subjects With Atopic Dermatitis
NCT05531188
Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis
NCT05644691
CLINICAL EFFICACY OF EMOLLIENTS IN ATOPIC DERMATITIS PATIENTS
NCT05783453
Evaluation and Comparison of 2 Cosmetic Investigational Products in Adults With Atopic Dermatitis
NCT03632174
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
NCT01577628
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* The qualitative variables are described with number and percent of each level.
* The quantitative variables are described with mean and standard deviation.
* All statistical hypotheses are performed at the 5% significance level using 2-sided tests.
* Given the large sample size, no normality assessment will be done.
* Mean reduction rate for quantitative variables is calculated as (mean v0 - mean v1)/mean v0)\*100.
* Due to the high number of zeros at inclusion in the self-assessment quantitative criteria, analyses will concern only patient with an intensity above 0 at inclusion or at final visit.
* Response rate for qualitative variables is calculated as the percent of patients with at least on level decrease between the two visits.
* Response rate for satisfaction is the percent of patients declaring being Satisfied or Very satisfied.
* Response rate for tolerance is the percent of patients declaring the tolerance High or Excellent.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cosmetique Active International
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Delphine Kerob
Role: STUDY_DIRECTOR
Cosmetique Active International
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermatology practices
Zagreb, , Croatia
Dermatology practices
Berlin, , Germany
Dermatology practices
Lisbon, , Portugal
Dermatology practices
Pretoria, , South Africa
Dermatology practices
Taipei, , Taiwan
Dermatology practices
Bangkok, , Thailand
Dermatology practices
Hanoi, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LRP20001-LIPIKAR BAUME AP+M
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.